Rescue strategies against non-steroidal anti-inflammatory drug-induced gastroduodenal damage

Journal of Gastroenterology and Hepatology (Australia)

Volumn 24, Issue 7, 2009, Pages 1169-1178

  Lim, Yun Jeong ^b   Lee, Jeong Sang ^a   Ku, Yang Suh ^a   Hahm, Ki Baik ^a  

^a Gachon University   (South Korea)

^b Dongguk University College of Medicine   (South Korea)

Author keywords

Cyclooxygenase; Gastroduodenal damage; Non steroidal anti inflammatory drug; Safety

Indexed keywords

ACEXAMATE ZINC; ACTIVATING TRANSCRIPTION FACTOR 6; CELECOXIB; CYCLOOXYGENASE 2; DEOXYRIBONUCLEASE I; DICLOFENAC; DP 155; GLUCOSE REGULATED PROTEIN 78; GLUCOSE REGULATED PROTEIN 94; HYDROGEN SULFIDE; IBUPROFEN; ICOSANOID; INDOMETACIN; INOSITOL; INTERCELLULAR ADHESION MOLECULE 1; LEUKOTRIENE B4; LICOFELONE; LIPOXIN A; MEFENAMIC ACID; NITRIC OXIDE DONOR; NITROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIROXICAM; POLAPREZINC; ROFECOXIB; SILDENAFIL; TENOXICAM; TEPOXALIN; TEPRENONE; UNCLASSIFIED DRUG; ZINC;

BLOOD VESSEL PERMEABILITY; CARDIOVASCULAR DISEASE; CELL DAMAGE; CELL PROLIFERATION; CELL RENEWAL; CELLULAR STRESS RESPONSE; DIGESTIVE SYSTEM INJURY; DOG; DRUG SAFETY; ENDOPLASMIC RETICULUM; ENDOTHELIUM CELL; ENZYME PHOSPHORYLATION; EPITHELIUM CELL; GASTRODUODENAL ULCER; GASTRODUODENUM DAMAGE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL SYMPTOM; HEMATOCRIT; HUMAN; HYDROPHOBICITY; LEUKOCYTE; LEUKOCYTE ADHERENCE; MITOCHONDRION; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PALLOR; PATHOGENESIS; PEPTIC ULCER BLEEDING; PERMEABILITY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STOMACH DISEASE; STOMACH EPITHELIUM; STOMACH MUCOSA; STOMACH MUCOSA BLOOD FLOW; STOMACH MUSCLE; STOMACH ULCER; TIGHT JUNCTION; ULCER; UPREGULATION; VASCULAR ENDOTHELIUM;

EID: 68749085157     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2009.05929.x     Document Type: Review

References (97)

1. Graham DY, Chan FKL. NSAIDs, risks, and gastroprotective strategies: current status and future. Gastroenterology 2008 134 : 1240 57.
2. Wallace JL. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology 1997 112 : 1000 18.
3. Hawkey CJ. Non-steroidal anti-inflammatory drug gastropathy: causes and treatment. Scand. J. Gastroenterol. 1996 31 (Suppl 124 7.
4. Hawkey CJ. Nonsteroidal anti-inflammatory drug gastropathy. Gastroenterology 2000 119 : 521 35.
5. Russell RI. Non-steroidal anti-inflammatory drugs and gastrointestinal damage-problems and solutions. Postgrad. Med. J. 2001 77 : 82 8.
6. Davies NM, Wallace JL. Nonsteroidal anti-inflammatory drug-induced gastrointestinal toxicity: new insights into an old problem. J. Gastroenterol. 1997 32 : 127 33.
7. Griffin MR. Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury. Am. J. Med. 1998 104 : 23S 29S.
8. Talley NJ, Evans JM, Fleming KC et al. Nonsteroidal anti-inflamatory drugs and dyspepsia in the elderly. Dig. Dis. Sci. 1995 40 : 1345 50.
9. Targownik LE, Metge CJ, Leung S et al. The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs. Gastroenterology 2008 134 : 937 44.
10. Helin-Salmivaara A, Saarelainen S, Gronroos JM et al. Risk of upper gastrointestinal events with the use of various NSAIDs; a case-control study in a general population. Scand. J. Gastroenterol. 2007 42 : 923 32.
11. Laine L, Takeuchi K, Tarnawski A. Gastric mucosal defense and cytoprotection: bench to bedside. Gastroenterology. 2008 135 : 41 60.
12. Scarpignato C. Nonsteroidal anti-inflammatory drugs; How do they damage gastroduodenal mucosa? Dig. Dis. 1995 13 (Suppl. 1 9 39.
13. Scheiman JM. NSAID-induced peptic ulcer disease; a critical review of pathogenesis and treatment. Dig. Dis. 1994 12 : 210 22.
14. Scheiman JM. The impact of nonsteroidal anti-inflammatory drug-induced gastropathy. Am. J. Manag. Care. 2001 7 : S10 14.
15. Rainsford KD. The effects of aspirin and other non-steriodal anti-inflammatory/analgesic drugs on gastrointestinal mucus glycoprotein biosynthesis in vivo: relationship to ulcerogenic action. Biochem. Pharmacol. 1978 27 : 877 85.
16. Ashley SW, Sonnenschein LA, Cheung LY. Focal gastric mucosal blood flow at the site of aspirin-induced ulceration. Am. J. Surg. 1985 149 : 53 9.
17. Funatsu T, Chono K, Hirata T, Keto Y, Kimoto A, Sasamata M. Mucosal acid causes gastric mucosal microcirculatory disturbance in nonsteroidal anti-inflammatory drug-treated rats. Eur. J. Pharmacol. 2007 554 : 53 9.
18. Fujiwara Y, Kang J, Fujiwara K, Chang K, Tarnawski A. Effect of nonsteroidal anti-inflammatory drug on cell proliferation in gastroduodenal mucosa. Eur. J. Gastroenterol. Hepatol. 1993 5 : 301 5.
19. Sun WH, Tsuji S, Tsuji M et al. Cyclo-oxygenase-2 inhibitors suppress epithelial cell kinetics and delay gastric wound healing in rats. J. Gastroenterol. Hepatol. 2000 15 : 752 61.
20. Goddard PJ, Hills BA, Lichtenberger LM. Does aspirin damage the stomach by decreasing gastric mucosal surface hydrophobicity? Gastroenterology 1985 88 : 1714.
21. Lichtenberger LM, Zhou Y, Dial EJ, Raphael RM. NSAID injury to the gastrointestinal track; evidence that NSAIDs interact with phospholipids to weaken hydrophobic surface barrier and induce formation of unstable pores in membranes. J. Pharm. Pharmacol. 2006 58 : 1421 8.
22. Patrono C, Patrignani P, Garcia Rodriguez LA. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J. Clin. Invest. 2001 108 : 7 13.
23. Halter F, Tarnawski A, Schmassmann A, Peskar BM. Cyclooxygenase 2-implications on maintenance of gastric mucosal integrity and ulcer healing: controversial issues and perspectives. Gut 2001 49 : 443 53.
24. Dinchuk JE, Car BD, Focht RJ et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 1995 378 : 406 9.
25. Panes J, Granger DN. Leukocyte-endothelial cell interactions: molecular mechanisms and implications in gastrointestinal disease. Gastroenterology. 1998 114 : 1066 90.
26. Abraham NS, Graham DY. NSAIDs and gastrointestinal complications; new clinical challenge. Expert. Opin. Pharmacother. 2005 6 : 2681 9.
27. Somasundaram S, Sigthorsson G, Simpson RJ et al. Uncoupling of intestinal mitochondrial oxidative phosphoraylation and inhibition of cyclooxygenase are required for development of NSAID-enteropathy in the rat. Aliment. Pharmacol. Ther. 2000 14 : 639 50.
28. Basivireddy J, Jacob M, Ramamoorthy P, Pulimood AB, Balasubramanian KA. Indomethacin-induced free radical-mediated changes in the intestinal brush border membranes. Biochem. Pharmacol. 2003 65 : 683 95.
29. Basivireddy J, Vasudevan A, Jacob M, Balasubramanian KA. Indomethacin-induced mitochondrial dysfunction and oxidative stress in villus enterocytes. Biochem. Pharmacol. 2002 64 : 339 49.
30. Ueki S, Takeuchi K, Okabe S. Gastric motility is an important factor in the pathogenesis of indomethacin-induced gastric mucosal lesions in rats. Dig. Dis. Sci. 1988 33 : 209 16.
31. Schroder M, Kaufman RJ. ER stress and the unfolded protein response. Mutat. Res. 2005 569 : 29 63.
32. Yoshida H. ER stress and diseases. FEBS Lett. 2007 274 : 630 58.
33. Wu J, Kaufman RJ. From acute ER stress to physiological roles of the unfolded protein response. Cell Death Diff. 2006 13 : 374 84.
34. Nozaki S, Sledge GW, Nakshatri H. Repression of GADD153/CHOP by NF-κB: a possible cellular defense against endoplasmic reticulum stress-induced cell death. Oncogene 2001 20 : 2178 85.
35. Yamazaki T, Muramoto M, Oe T et al. Diclofenac, a non-steroidal anti-inflammatory drug, suppresses apoptosis induced by endoplasmic reticulum stresses by inhibiting caspase signaling. Neuro. Pharmacol. 2006 50 : 558 67.
36. Ma Y, Hendershot LM. The role of the unfolded protein response in tumor development: friend or foe. Nat. Rev. Cancer 2004 4 : 966 77.
37. Tsutumi S, Gotoh T, Tomisato W. et al. Endoplasmic reticulum stress response is involved in nonsteroidal anti-inflammatory drug-induced apoptosis. Cell Death Differ. 2004 11 : 1009 16.
38. Marciniak SJ, Ron D. Endoplasmic reticulum stress signaling in disease. Physiol. Rev. 2006 86 : 1133 49.
39. Suleyman H, Demircan B, Karagoz Y. Anti-inflammatory and side effects of cyclooxygenase inhibitors. Pharmacol. Rep. 2007 59 : 247 58.
40. Dubuquoy L, Rousseaux C, Thuru X et al. PPARγ as a new therapeutic target in inflammatory bowel disease. Gut 2006 55 : 1341 9.
41. Wick M, Hutreau G, Dessev C et al. Peroxisome proliferators-activated receptor-γ is a target of non-steroidal anti-inflammatory drug mediating cyclooxygenase-independent inhibition of lung cancer cell growth. Mol. Pharmacol. 2002 62 : 1207 14.
42. Szabo C. Hydrogen sulphide and its therapeutic potential. Nat. Rev. Drug Discov. 2007 6 : 917 35.
43. Zanardo RCO, Brancaleone V, Distrutti E, Fiorucci S, Cirino G, Wallace JL. Hydrogen sulfide is an endogenous modulator of leukocyte-mediated inflammation. FASEB J. 2006 20 : 1411 18.
44. Masubuchi Y, Yamada S, Horie T. Diphenylamine as an important structure of nonsteroidal anti-inflammatory drugs to uncouple mitochondrial oxidative phosphorylation. Biochem. Pharmacol. 1999 58 : 861 5.
45. Redlak MJ, Power JJ, Miller TA. Role of mitochondria in aspirin-induced apoptosis in human gastric epithelial cells. Am. J. Physiol. Gastrointest. Liver Physiol. 2005 289 : G731 8.
46. Aburaya M, Tanaka KI, Hoshino T et al. Heme oxidase-1 protects gastric mucosal cells against non-steroidal anti-inflammatory drugs. J. Biol. Chem. 2006 281 : 33422 32.
47. Horvath K, Varga C, Berko A, Posa A, Laszio F, Whittle BJR. The involvement of heme oxidase-1 activity in the therapeutic actions of 5-aminosalicylic acid in rat colitis. Eur. J. Pharmacol. 2008 581 : 315 23.
48. Schwab JM, Serhan CN. Lipoxins and new lipid mediators in the resolution of inflammation. Curr. Opin. Pharmacol. 2006 6 : 414 20.
49. Serhan CN. Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution. Prostaglandins Leukot. Essent. Fatty Acids 2005 73 : 141 62.
50. Svensson CI, Zattoni M, Serhan CN. Lipoxins and aspirin-triggered lipoxin inhibit inflammatory pain processing. J. Exp. Med. 2007 204 : 245 52.
51. Petasis NA, Keledjian R, Sun YP et al. Design and synthesis of benzo-lipoxin A4 analogs with enhanced stability and potent anti-inflammatory properties. Bioorganic. Med. Chem. Lett. 2008 18 : 1382 7.
52. Wallace JL, Caliendo G, Santagada V, Cirino G, Fiorucci S. Gastrointestinal safety and anti-inflammatory effects of a hydrogen sulfide-releasing diclofenac derivative in the rat. Gastroenterology. 2007 132 : 261 71.
53. Fiorucci S, Antonelli E, Distrutti E et al. Inhibition of hydrogen sulfide generation contributes to gastric injury caused by anti-inflammatory nonsteroidal drugs. Gastroenterology. 2005 129 : 1210 24.
54. 2S-releasing NSAIDs: what lies beyond the horizon. Dig. Liver. Dis. 2007 39 : 1043 51.
55. 2S) the third gas of interest for pharmacologists. Pharmacol. Reports. 2007 59 : 4 24.
56. Wallace JL. Building a better aspirin; gaseous solutions to a century-old problem. Br. J. Pharmacol. 2007 152 : 421 8.
57. Yoo SH, Jung HS, Sohn WS et al. Volatile sulfure compounds as a predictor for esophagogastroduodenal mucosal injury. Gut. Liver 2008 2 : 113 18.
58. Lichtenberger LM, Omero JJ, Dial EJ. Surface phospholipids in gastric injury and protection when a selective cyclooxygenase-2 inhibitor (Coxib) is used in combination with aspirin. Br. J. Pharmacol. 2007 150 : 913 19.
59. Boinpally RR, Zhou SL, Poondru S, Cevraj G, Jasti BR. Lecithin vesicles for topical delivery of diclofenac. Eur. J. Pharm. Biopharm. 2003 56 : 389 92.
60. Lanza FL, Marathi UK, Arand BS, Lichtenbergers LM. Clinical trial: comparison of ibuprofen-phosphatidylcholine and ibuprofen on the gastrointestinal safety and analgesic efficacy in osteoarthritic patients. Aliment. Pharmacol. Ther. 2008 28 : 431 42.
61. Dvir E, Friedman JE, Lee TY et al. A novel phospholipid derivative of indomethacin, DP-155 [mixture of 1-steroyl and 1-palmitoyl-2-{6-[1-(p- chlorobenzoyl)-5-methoxy-2-methyl-3-indolyl acetamido]hexanoyl}-sn-glycero-3- phosophatidyl [corrected] choline], shows superior safety and similar efficacy in reducing brain amyloid beta in an Alzheimer's disease model. J. Pharmacol. Exp. Ther. 2006 318 : 1248 56.
62. Lichetenberger LM, Romero JJ, De Fuijter WMJ et al. Phosphatidylcholine association increases the anti-inflammatory and analgesic activity of ibuprofen in acute and chronic rodent models of joint inflammation; relationship to alterations in bioavailability and cyclooxygenase-inhibitory potency. J. Pharmacol. Exp. Ther. 2001 298 : 279 87.
63. Chakraborty H, Mondal S, Sarkar M. Membrane fusion: a new function of non steroidal anti-inflammatory drugs. Biophys. Chem. 2008 137 : 28 34.
64. Santos LH, Feres CA, Melo FH et al. Anti-inflammatory, antinociceptive and ulcerogenic activity of a zinc-diclofenac complex in rats. Braz. J. Med. Biol. Res. 2004 37 : 1205 13.
65. Tran CD, Campbell MAF, Kolev Y, Chamberlain S, Huynh HQ, Butler RN. Short-term zinc supplementation attenuates Helicoabcter felis-induced gastritis in the mouse. J. Infect. 2005 50 : 417 24.
66. Sharma J, Singla AK, Dhawan S. Zinc-naproxen: synthesis, physicochemical and biological evaluation. Int. J. Pharm. 2003 260 : 217 27.
67. Davies NM, Roseth AG, Appleyard CB et al. NO-naproxen vs. naproxen: ulcerogenic, analgesic and anti-inflammatory effects. Aliment. Pharmacol. Ther. 1997 11 : 69 79.
68. Elliott SN, Mcknight W, Cirino G, Wallase JL. Nitric oxide-releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats. Gastroenterology. 1995 109 : 524 30.
69. Jansson EA, Petersson J, Reinders C et al. Protection from nonsteroidal anti-inflammatory drug (NSAID)-induced gastric ulcers by dietary nitrate. Free. Rad. Biol. Med. 2007 42 : 510 8.
70. Sawatzky DA, Megson IL, Rossi AG. Sidenafil offers protection against NSAID-induced gastric injury. Br. J. Pharmacol. 2005 146 : 477 8.
71. Aydinli B, Yildirgan MI, Oztürk G et al. The role of sildenafil citrate in the protection of gastric mucosa from nonsteroidal anti-inflammatory drug-induced damage. Ulus. Travma. Acil. Cerrahi. Derg. 2007 13 : 268 73.
72. Fiorucci S, Meli R, Bucci M, Cirino G. Dual inhibitors of cyclooxygenase and 5-lipoxygenase A new avenue in anti-inflammatory therapy? Biochem. Pharmacol. 2001 62 : 1433 8.
73. Bertolini A, Sandrini M. Dual acting anti-inflammatory drugs; a reappraisal. Pharmacol. Res. 2001 44 : 437 50.
74. Gyomber E, Vattay P, Szabo S, Rainsford KD. Effect of lipoxygenase inhibitors and leukotriene anatagonists on acute and chronic gastric hemorrhagic mucosal lesions in ulcer models in the rat. J. Gastroenterol. Hepatol. 1996 11 : 922 7.
75. Ushijima H, Tanaka KI, Takeda M, Katsu T, Mima S, Mizushima T. Geranylgeranylacetone protects membranes against nonsteroidal anti-inflammatory drugs. Mol. Pharmacol. 2005 68 : 1156 61.
76. Park SH, Cho CS, Lee OH et al. Comparison of prevention of NSAID-induced gastrointestinal complications by rebamipide and misoprostol: a randomized, multicenter, controlled trial-STORM STUDY. J. Clin. Biochem. Nutr. 2007 40 : 148 55.
77. Mizoguchi H, Ogawa Y, Kanatsu K, Tanaka A, Kato S, Takeuchi K. Protective effect of rebamipide on indomethacin-induced intestinal damage in rats. J. Gastroenterol. Hepatol. 2001 16 : 1112 19.
78. Okuyama K, Jinbo M, Saito N, Igarashi S, Narita H, Kinoshita H. Role of mucus reduction and luminal acid elevation in increased susceptibility of stomach to nonsteroidal anti-inflammatory drug-induced injury in arthritic rats. Dig. Dis. Sci. 2000 45 : 2175 81.
79. Mohmood A, FitzGerald AJ, Marchbank T et al. Zinc carosine, a health food supplement that stabilized small bowel integrity and stimulates gut repair processes. Gut 2007 56 : 168 75.
80. King JC, Shames DM, Woodhouse LR. Zinc homeostasis in humans. J. Nutr. 2000 130 : S1360 6.
81. Matsuu-Matsuyama M, Shichijo K, Okaichi K et al. Protection by polaprezinc against radiation-induced apoptosis in rat jejunal crypt cells. J. Radiat. Res. 2008 49 : 341 7.
82. Ishihara R, Iish H Sakain N et al. Polaprezinc attenuates Helicobacter pylori-associated gastritis in Mongolian gerbils. Helicobacter. 2002 7 : 384 9.
83. Fuji Y, Matsura T, Kai M, Kawasaki H, Yamada K. Protection by polaprezinc, an anti-ulcer drug, against indomethacin-induced apoptosis in rat gastric mucosal cells. Jpn. J. Pharmacol. 2000 84 : 63 70. (Pubitemid 30777261)
84. Mahmood A, FitzGerald AJ, Marchbank T et al. Zinc carnosine, a health food supplement that stabilizes small bowel integrity and stimulates gut repair processes. Gut. 2007 56 : 168 75.
85. Sugino H, Kumagai N, Watanabe S et al. Polaprezinc attenuates liver fibrosis in a mouse model of non-alcoholic steatohepatitis. J. Gastroenterol. Hepatol. 2008 23 : 1909 16.
86. Katayama S, Nishizawa K, Hirano M, Yamamura S, Momose Y., Katayama S Nishizawa Effect of polaprezinc on healing of acetic acid-induced stomatitis in hamsters. J. Pharm. Pharm. Sci. 2000 3 : 114 17.
87. Matsukura T, Tanaka H. Applicability of zinc complex of L-carnosine for medical use. Biochemistry 2000 65 : 961 8.
88. Shimada T, Watanabe N, Ohtsuka Y et al. Polaprezinc down-regulates proinflammatory cytokine-induced nuclear factor-kappaB activiation and interleukin-8 expression in gastric epithelial cells. J. Pharmacol. Exp. Ther. 1999 291 : 345 52.
89. Watanabe S, Wang XE, Hirose M et al. Insulin-like growth factor I plays a role in gastric wound healing: evidence using a zinc derivative, polaprezinc, and an in vitro rabbit wound repair model. Aliment. Pharmacol. Ther. 1998 12 : 1131 8.
90. Escolar G, Camarasa J, Navarro C, Vernetta C, Bulbena O. Antiulcerogenic activity of zinc acexamate in different experimental models. Methods Find. Exp. Clin. Pharmacol. 1987 9 : 423 7.
91. Bulbena O, Esplugues JV, Escolar G, Navarro C, Esplugues J. Effects of zinc acexamate on blood flow and prostanoid levels in the gastric mucosa of the rat. Prostaglandins Leukot. Essent. Fatty Acids 1989 36 : 119 23.
92. Bravo L, Escolar G, Navarro C, Fontarnau R, Bulbena O. Effects of zinc acexamate on gastric lesions induced by aspirin: a morphological study. Eur. J. Pharmacol. 1990 190 : 59 65.
93. Navarro C, Bravo ML, Carulla C, Bulbena O. Gastrotoxic activity and inhibitory effects on gastric mucosal PGE2 production with different non-steroidal anti-inflammatory drugs: modifications induced by pretreatment with zinc acexamate. Prostaglandins Leukot. Essent. Fatty Acids 1994 50 : 305 10.
94. Tsutsui Y, Nakamura Y, Yamaguchi S, Kawanaka N, Sato M. Effects of zinc acexamate (NAS-501) on superoxide radicals and lipid peroxidation of rat gastric mucosa. Pharmacology. 1999 58 : 209 19.
95. Rodríguez de la Serna A, Díaz-Rubio M. Multicenter clinical trial of zinc acexamate in the prevention of nonsteroidal anti-inflammatory drug induced gastroenteropathy. Spanish Study Group on NSAID Induced Gastroenteropathy Prevention. J. Rheumatol. 1994 21 : 927 33.
96. Devchand PR. Lipoxin agonists: turn right! To path of resolving neutrophil. Mem. Inst. Oswaldo Cruz. 2005 100 : 55 7.
97. Rigas B, Williams JL. NO-donating NSAIDs and cancer: an overview with a note on whether NO -s required for their action. Nitric Oxide 2008 19 : 199 204.